<DOC>
	<DOCNO>NCT01426230</DOCNO>
	<brief_summary>Study objective ass safety effectiveness once- daily GRALISE clinical practice</brief_summary>
	<brief_title>Phase IV Study FDA Approved , Once-Daily GRALISEâ„¢ ( Gabapentin ) Tablets Treatment Postherpetic Neuralgia</brief_title>
	<detailed_description>Open Label , single arm , 2wk titration , 6 wk stable dosing , 8 wk total treatment , 1wk dose tapering</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<criteria>Men Women 18 year old suffer PHN Patient Pregnant nursing mother Patient hypersensitivity gabapentin Patient estimate creatinine clearance &lt; 30 mL/min hemodialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>PHN</keyword>
	<keyword>Post Herpetic Neuralgia</keyword>
	<keyword>Shingles</keyword>
	<keyword>HZ roster</keyword>
</DOC>